Product nameProtease and Phosphatase Inhibitor Cocktail
To protect against both protease and phosphatase in one solution try our dual cocktail (EDTA-free also available).
AEBSF free and mass spectroscopy compatible – water soluble.
Target proteases - serine proteases, aminopeptidase B, leucine aminopeptidase, cysteine proteases, metalloproteases
Target phosphatases - serine/threonine phosphatases, acid phosphatases, protein tyrosine phosphatases, alkaline phosphatases
Inhibitors included - aprotinin (bovine lung), bestatin, E-64, leupeptin hemisulfate, β-glycerophosphate, sodium fluoride, sodium orthovanadate, sodium pyrophosphate decahydrate, EDTA disodium salt.
Form: Supplied as 1 vial of cocktail in water (1 ml) and 1 vial of EDTA disodium salt (0.5 mM in 1 ml of water)
Preparation: The recommended starting dilution is 1:9
Visit our inhibitor cocktails page for more information on our complete range of convenient and easy to use protease and phosphatase inhibitor cocktails.
Individual components and concentration:
Aprotinin (bovine lung): serine protease inhibitor (0.08 mM)
Bestatin: aminopeptidase B and leucine aminopeptidase inhibitor (5 mM)
E-64: cysteine protease inhibitor (1.5 mM)
Leupeptin hemisulfate: serine/cysteine protease inhibitor (2 mM)
β-Glycerophosphate: serine/threonine phosphatase inhibitor (10 mM)
Sodium fluoride: acid phosphatase and serine/threonine phosphatase inhibitor (50 mM)
Sodium orthovanadate: protein tyrosine phosphatase and alkaline phosphatase inhibitor (1 mM)
Sodium pyrophosphate decahydrate: serine/threonine phosphatase inhibitor (10 mM)
EDTA disodium salt: metalloprotease inhibitor (0.5 mM)
Storage instructionsStore at -20°C. Please refer to protocols.
Components Identifier 1 kit EDTA Solution (10X) Clear 1 x 1ml Protease and Phosphatase Inhibitor Cocktail (10X) Red 1 x 1ml
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab201119 has been referenced in 10 publications.
- Borras C et al. Mechanisms of FH Protection Against Neovascular AMD. Front Immunol 11:443 (2020). PubMed: 32318056
- Luo R et al. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy 16:52-69 (2020). PubMed: 30898012
- Lodge EJ et al. Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade. Elife 8:N/A (2019). PubMed: 30912742
- Zhou C et al. Expression and localization of MrgprD in mouse intestinal tract. Cell Tissue Res N/A:N/A (2019). PubMed: 30919047
- Lin X et al. Treatment With 2-BFI Attenuated Spinal Cord Injury by Inhibiting Oxidative Stress and Neuronal Apoptosis via the Nrf2 Signaling Pathway. Front Cell Neurosci 13:567 (2019). PubMed: 31920564
- You Q et al. MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. Oncol Lett 16:2326-2334 (2018). PubMed: 30008936
- Feng D et al. Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells. Oncol Lett 13:2758-2764 (2017). WB . PubMed: 28454463
- Gama Sosa MA et al. Lack of chronic neuroinflammation in the absence of focal hemorrhage in a rat model of low-energy blast-induced TBI. Acta Neuropathol Commun 5:80 (2017). PubMed: 29126430
- Wang B et al. Essential control of mitochondrial morphology and function by chaperone-mediated autophagy through degradation of PARK7. Autophagy 12:1215-28 (2016). PubMed: 27171370
- Buenrostro-Jáuregui M et al. Changes in CREB and deltaFosB are associated with the behavioural sensitization induced by methylenedioxypyrovalerone. J Psychopharmacol 30:707-12 (2016). PubMed: 27147595